Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

monoclonal antibodies

  • You have access
    Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3
    Joshua Aaron Korsen, Teja Muralidhar Kalidindi, Samantha Khitrov, Zachary V. Samuels, Goutam Chakraborty, Julia A. Gutierrez, John T. Poirier, Charles M. Rudin, Yu Chen, Michael J. Morris, NagaVaraKishore Pillarsetty and Jason S. Lewis
    Journal of Nuclear Medicine January 20, 2022, jnumed.121.263221; DOI: https://doi.org/10.2967/jnumed.121.263221
  • You have access
    Optimizing immunoPET imaging of tumor PD-L1 expression: pharmacokinetics, biodistribution and dosimetric comparisons of 89Zr-labeled anti-PD-L1 antibody formats
    ALIZEE BOULEAU, HERVE NOZACH, STEVEN DUBOIS, DIMITRI KERESELIDZE, CELINE CHEVALEYRE, CHENG-I WANG, Michael John Evans, VINCENT LEBON, BERNARD MAILLERE and Charles TRUILLET
    Journal of Nuclear Medicine December 21, 2021, jnumed.121.262967; DOI: https://doi.org/10.2967/jnumed.121.262967
  • You have access
    Affibody-mediated PNA-based pretargeted co-treatment improves survival of trastuzumab-treated mice bearing HER2-expressing xenografts
    Maryam Oroujeni, Hanna Tano, Anzhelika Vorobyeva, Yongsheng Liu, Olga Vorontsova, Tianqi Xu, Kristina Westerlund, Anna Orlova, Vladimir Tolmachev and Amelie Eriksson Karlström
    Journal of Nuclear Medicine October 28, 2021, jnumed.121.262123; DOI: https://doi.org/10.2967/jnumed.121.262123
  • You have access
    The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals
    Guus A.M.S. van Dongen, Wissam Beaino, Albert D. Windhorst, Gerben J.C. Zwezerijnen, Daniela E. Oprea-Lager, N. Harry Hendrikse, Cornelis van Kuijk, Ronald Boellaard, Marc C. Huisman and Danielle J. Vugts
    Journal of Nuclear Medicine April 1, 2021, 62 (4) 438-445; DOI: https://doi.org/10.2967/jnumed.119.239558
  • You have access
    89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo
    Yvonne W.S. Jauw, Joseph A. O’Donoghue, Josée M. Zijlstra, Otto S. Hoekstra, C. Willemien Menke-van der Houven van Oordt, Franck Morschhauser, Jorge A. Carrasquillo, Sonja Zweegman, Neeta Pandit-Taskar, Adriaan A. Lammertsma, Guus. A.M.S. van Dongen, Ronald Boellaard, Wolfgang A. Weber and Marc C. Huisman
    Journal of Nuclear Medicine December 1, 2019, 60 (12) 1825-1832; DOI: https://doi.org/10.2967/jnumed.118.224568
  • Open Access
    Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
    Katrine Wickstroem, Urs B. Hagemann, Véronique Cruciani, Antje M. Wengner, Alexander Kristian, Christine Ellingsen, Gerhard Siemeister, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Lars Linden, Dominik Mumberg, Karl Ziegelbauer and Alan S. Cuthbertson
    Journal of Nuclear Medicine September 1, 2019, 60 (9) 1293-1300; DOI: https://doi.org/10.2967/jnumed.118.223701
  • You have access
    Theranostics Using Antibodies and Antibody-Related Therapeutics
    Kirsten L. Moek, Danique Giesen, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Rudolf S.N. Fehrmann, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers and Elisabeth G.E. de Vries
    Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 83S-90S; DOI: https://doi.org/10.2967/jnumed.116.186940
  • You have access
    Development of 124I Immuno-PET Targeting Tumor Vascular TEM1/Endosialin
    Ann-Marie Chacko, Chunsheng Li, Madhura Nayak, John L. Mikitsh, Jia Hu, Catherine Hou, Luigi Grasso, Nicholas C. Nicolaides, Vladimir R. Muzykantov, Chaitanya R. Divgi and George Coukos
    Journal of Nuclear Medicine March 1, 2014, 55 (3) 500-507; DOI: https://doi.org/10.2967/jnumed.113.121905
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire